IL226449A0 - פורמולציה מורכבת המכילה לרקנידיפין@הידרוכלוריד@וואלסרטאן@ושיטה@להכנתה - Google Patents

פורמולציה מורכבת המכילה לרקנידיפין@הידרוכלוריד@וואלסרטאן@ושיטה@להכנתה

Info

Publication number
IL226449A0
IL226449A0 IL226449A IL22644913A IL226449A0 IL 226449 A0 IL226449 A0 IL 226449A0 IL 226449 A IL226449 A IL 226449A IL 22644913 A IL22644913 A IL 22644913A IL 226449 A0 IL226449 A0 IL 226449A0
Authority
IL
Israel
Prior art keywords
valsartan
preparation
lercanidipine hydrochloride
complex formulation
formulation
Prior art date
Application number
IL226449A
Other languages
English (en)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226449(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of IL226449A0 publication Critical patent/IL226449A0/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL226449A 2010-12-09 2013-05-20 פורמולציה מורכבת המכילה לרקנידיפין@הידרוכלוריד@וואלסרטאן@ושיטה@להכנתה IL226449A0 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
IL226449A0 true IL226449A0 (he) 2013-07-31

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226449A IL226449A0 (he) 2010-12-09 2013-05-20 פורמולציה מורכבת המכילה לרקנידיפין@הידרוכלוריד@וואלסרטאן@ושיטה@להכנתה

Country Status (17)

Country Link
EP (1) EP2648730A4 (he)
KR (1) KR101414814B1 (he)
CN (1) CN103249415B (he)
AR (1) AR084195A1 (he)
AU (1) AU2011339150B2 (he)
BR (1) BR112013013415A2 (he)
CL (1) CL2013001626A1 (he)
CO (1) CO6721030A2 (he)
DO (1) DOP2013000115A (he)
EA (1) EA201390844A1 (he)
IL (1) IL226449A0 (he)
MX (1) MX2013005716A (he)
PE (1) PE20140699A1 (he)
SG (1) SG190326A1 (he)
UA (1) UA108277C2 (he)
UY (1) UY33772A (he)
WO (1) WO2012077968A2 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业(广州)有限公司 一种乐卡地平和阿托伐他汀复方制剂
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
UY33772A (es) 2012-07-31
CN103249415A (zh) 2013-08-14
KR20120089787A (ko) 2012-08-13
SG190326A1 (en) 2013-06-28
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
DOP2013000115A (es) 2014-07-31
AR084195A1 (es) 2013-04-24
PE20140699A1 (es) 2014-06-13
EA201390844A1 (ru) 2013-11-29
CO6721030A2 (es) 2013-07-31
AU2011339150A1 (en) 2013-06-06
WO2012077968A3 (en) 2012-07-26
EP2648730A4 (en) 2014-08-06
CN103249415B (zh) 2017-12-12
KR101414814B1 (ko) 2014-07-21
BR112013013415A2 (pt) 2019-09-24
MX2013005716A (es) 2013-06-12
CL2013001626A1 (es) 2013-10-04
WO2012077968A2 (en) 2012-06-14
UA108277C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
IL269804A (he) תצמידים של חומר חלבון פעיל ושיטה להכנתם
GB2477588B (en) Self-making bread method, bread machine and bread ingredient box thereof
GB201116610D0 (en) A copolymer and preparation method and application thereof
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
IL216171A (he) תרכובת ליפידית, שיטה להכנת התרכובת, תכשיר רוקחי ותכשיר ליפידי המכילים את התרכובת ושימושים שלהם
EP2578584A4 (en) ARYLAMINE DERIVATIVES OF PURINE, PROCESS FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE
EP2603546A4 (en) POLYSILOXANE-POLYLACTIC BLOCK COPOLYMER AND PROCESS FOR PREPARING THE SAME
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
EP2573072A4 (en) INDENOQUINOLONE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
EP2607076A4 (en) PERSPECTIVE FILM AND MANUFACTURING METHOD THEREFOR
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
AP2013006842A0 (en) Lubricating composition and method for the preparation thereof
EP2781512A4 (en) OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA201206740B (en) Aildenafil citrate crystal form o,preparation method and use thereof
IL226449A0 (he) פורמולציה מורכבת המכילה לרקנידיפין@הידרוכלוריד@וואלסרטאן@ושיטה@להכנתה
EP2636675A4 (en) DIPHOSPHONATE COMPOUNDS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP2837380A4 (en) LERCANIDIPINHYDROCHLORIDE AND CALIUM LOSARTAN COMBINATION PREPARATION AND MANUFACTURING METHOD THEREFOR
EP2634184A4 (en) C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
HK1186185A1 (zh) 咪唑衍生物、製備方法及用途
EP2617293A4 (en) INGREDIENT MASKING AMERTUME AND METHOD OF MASKING AMERTUME
EP2565180A4 (en) ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH
PL2736496T3 (pl) Kompozycja farmaceutyczna zawierająca środek przeciwmuskarynowy i sposób jej wytwarzania
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof